These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 30843385

  • 21. Pt(IV) complexes as prodrugs for cisplatin.
    Shi Y, Liu SA, Kerwood DJ, Goodisman J, Dabrowiak JC.
    J Inorg Biochem; 2012 Feb; 107(1):6-14. PubMed ID: 22169035
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.
    Song Y, Suntharalingam K, Yeung JS, Royzen M, Lippard SJ.
    Bioconjug Chem; 2013 Oct 16; 24(10):1733-40. PubMed ID: 23957697
    [Abstract] [Full Text] [Related]

  • 23. Expanding the Arsenal of PtIV Anticancer Agents: Multi-action PtIV Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group.
    Yempala T, Babu T, Karmakar S, Nemirovski A, Ishan M, Gandin V, Gibson D.
    Angew Chem Int Ed Engl; 2019 Dec 09; 58(50):18218-18223. PubMed ID: 31599054
    [Abstract] [Full Text] [Related]

  • 24. The reduction of cis-platinum(iv) complexes by ascorbate and in whole human blood models using 1H NMR and XANES spectroscopy.
    Chen CKJ, Kappen P, Hambley TW.
    Metallomics; 2019 Mar 20; 11(3):686-695. PubMed ID: 30839039
    [Abstract] [Full Text] [Related]

  • 25. New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.
    Nemirovski A, Vinograd I, Takrouri K, Mijovilovich A, Rompel A, Gibson D.
    Chem Commun (Camb); 2010 Mar 21; 46(11):1842-4. PubMed ID: 20198227
    [Abstract] [Full Text] [Related]

  • 26. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.
    Novohradsky V, Zerzankova L, Stepankova J, Vrana O, Raveendran R, Gibson D, Kasparkova J, Brabec V.
    Biochem Pharmacol; 2015 Jun 01; 95(3):133-44. PubMed ID: 25888926
    [Abstract] [Full Text] [Related]

  • 33. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH, al-Baker S, Thai G, Khokhar AR.
    Anticancer Drug Des; 1994 Apr 01; 9(2):139-51. PubMed ID: 8166929
    [Abstract] [Full Text] [Related]

  • 34. Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)2I2(en)]: a novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro.
    Kratochwil NA, Zabel M, Range KJ, Bednarski PJ.
    J Med Chem; 1996 Jun 21; 39(13):2499-507. PubMed ID: 8691447
    [Abstract] [Full Text] [Related]

  • 35. L-selenomethionine reduces platinum(IV) anticancer model compounds at strikingly faster rates than L-methionine.
    Huo S, Dong J, Shen S, Ren Y, Song C, Xu J, Shi T.
    Dalton Trans; 2014 Nov 07; 43(41):15328-36. PubMed ID: 25075569
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines.
    Pichler V, Göschl S, Schreiber-Brynzak E, Jakupec MA, Galanski M, Keppler BK.
    Metallomics; 2015 Jul 07; 7(7):1078-90. PubMed ID: 26073554
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.